Independent education resourceInformation here does not replace care from a qualified health professional.
Peptide Therapy GuideClear peptide education

Educational guide

Thymalin vs Thymopentin (TP-5) — Peptide Comparison

At a Glance Quickcomparison Dose Range Thymalin 5–10 mg Thymopentin (TP-5) 1–2 mg Frequency Once daily Administration Intramuscular injection Subcutaneous injection Cycle Length 4-6 weeks Onset Speed Moderate (1-2 weeks) Evidence Level Limited human trials Mod

Written by Peptide Therapy Guide Editorial Team
For education only

This guide cannot diagnose a condition or recommend a personal treatment plan. Discuss medical questions with a qualified professional.

At a Glance

Quickcomparison

Dose Range

Thymalin

5–10 mg

Thymopentin (TP-5)

1–2 mg

Frequency

Once daily

Administration

Intramuscular injection

Subcutaneous injection

Cycle Length

4-6 weeks

Onset Speed

Moderate (1-2 weeks)

Evidence Level

Limited human trials

Moderate human trials (Phase 1-2)

Efficacy

Benefitratings

Immune Restoration

Longevity Support

Disease Prevention

Immune Enhancement

Cardiovascular Support

Post-Recovery Support

Technical Data

Compoundspecifications

Molecular Formula

Complex mixture; active dipeptide EW: C16H19N3O5

Molecular Weight

Polypeptide complex; components 250-1000 Da; active dipeptide EW ~321 Da

Half-Life

Not precisely characterized for complex; immune effects persist weeks post-administration

Bioavailability

High via intramuscular or subcutaneous injection

CAS Number

63958-90-7

C30H49N9O9

679.8

30 seconds to few minutes in plasma

Sustained release via subcutaneous route

69558-55-0

Protocols

Dosingtiers

standard

5-10 mg reconstituted in saline

5-10 day course, often repeated every 6 months

Reflects the Russian clinical course used in immune-restoration and gerontology protocols, typically 10 mg IM daily for 5-10 days [1].

advanced

10 mg

Up to 20 day course, repeated every 6 months

Subcutaneous administration is used in community practice at the same 10 mg daily dosing; longer 20-day courses are described for cyclical immune support [1].

50 mg

Three times weekly

6 weeks to 48 weeks depending on indication

Dose used in controlled clinical trials, e.g. 50 mg SC three times weekly in HIV and atopic dermatitis studies [5].

50 mg by slow IV

Repeated injections (e.g. three times weekly)

Several weeks

Slow intravenous infusion was used in rheumatoid arthritis trials and may enhance in-vivo potency versus bolus dosing [5].

Applications

Bestsuited for

Aging Adults Seeking Immune Support

Thymalin is especially valuable for people over 55 whose thymus gland has naturally shrunk with age. By stimulating thymic function, it helps restore the immune training center that your body relies on to fight infections and stay healthy.

Longevity and Anti-Aging Protocols

Clinical studies tracking patients for 6-8 years showed Thymalin reduced mortality by 2.0-2.1-fold. Combined with Epitalon, the mortality reduction reached an impressive 4.1-fold, making this combination one of the most studied longevity peptide protocols.

Seasonal Illness Prevention

Research shows Thymalin cuts respiratory infection rates by 2.0-2.4-fold. A short 10-day course before cold and flu season can significantly boost your immune defenses for months afterward.

Immune System Enhancement

Thymopentin directly increases T-cell function and promotes dendritic cell maturation, making it ideal for people seeking to boost immune response naturally

Cardiac Health Support

Clinical trials show thymopentin improves ejection fraction and exercise capacity in elderly heart failure patients while enhancing immune markers

Post-Surgery Recovery

Helps restore immune function after major surgery and protects important immune responses during recovery period

Safety Profile

Sideeffects

Common

No side effects in most patients

Mild injection site reaction

Uncommon

Transient low-grade fever

Mild flu-like symptoms

Temporary headache

Serious

Severe allergic reaction

Local injection site reaction

Mild fatigue

Transient fever

Muscle aches

Mild headache

Allergic reaction

Research Status

Safety& evidence

FDA Status

Research compound

Safety Overview

Thymalin has an excellent safety profile based on over 40 years of clinical use in Russia. Most patients experience zero side effects, and the peptide complex has been described as 'practically non-toxic' in research literature. It has been used safely in thousands of patients, including elderly populations over extended periods.

Contraindications

xActive thymic tumors or malignancies

xKnown hypersensitivity to animal-derived peptide products

xPregnancy and breastfeeding (insufficient safety data)

xSevere uncontrolled autoimmune disease without medical supervision

Thymopentin is well-tolerated with minimal side effects reported in clinical trials. Most adverse events are mild and local. No serious safety concerns have emerged from decades of clinical use in China and Europe.

xPregnancy and breastfeeding

xActive malignancy (without medical supervision)

xSevere immunosuppression

xHypersensitivity to peptide medications

Decision Guide

Which isright for you?

Choose Thymalin if...

Immune system restoration in aging adults

Longevity and healthy aging support

Reducing infection frequency and severity

Multi-system health optimization

Choose Thymopentin (TP-5) if...

Immune system strengthening

Recovering from illness or surgery

Managing autoimmune conditions

Supporting cardiac health in elderly patients

Connected reading

Helpful context for this guide

Source-derived material selected through this article’s indexed topics.

Research context

Read sources and limitations before applying a claim.

Safety& evidence

FDA Status Not FDA approved Safety Overview Intermedin (Adrenomedullin-2) is an endogenous peptide hormone with systemic vascular and renal effects that warrant cautious use. As a vasodilator acting through CGRP and other peptide receptors, it can significantly lower blood pressure—a key safety consideration for hypotensive or cardiovascular-compromised individuals. Preclinical studies show dose-dependent hypotensive effects and tachycardia, limiting clinical translation. The compound remains largely experimental with limited safety data in humans outside specific research contexts. Contraindications xPregnancy and breastfeeding - insufficient safety data xActive cardiovascular events (heart attack, stroke) xSevere renal (kidney) impairment xHypersensitivity to calcitonin family peptides xUncontrolled endocrine disorders Research compound Adrenomedullin safety in humans is poorly characterized, with clinical data limited to observational studies and small uncontrolled trials in cardiovascular patients. Animal studies demonstrate potent vasodilatory effects that could lower blood pressure dangerously, particularly in patients on antihypertensive medications. No human pharmacokinetic studies have established safe doses, and potential for hypotension, electrolyte disturbances, and off-target vasodilation effects exists. The peptide crosses the blood-brain barrier and affects central nervous system function in animal models, raising concerns about neurological effects at higher doses. xSevere hypotension or shock states xConcurrent use with certain vasopressor medications xPregnancy and breastfeeding xSevere kidney or liver dysfunction Decision Guide

Source: peptideinitiative.com ↗

Safety& evidence

FDA Status Research compound Safety Overview Crystagen is a crystalline protein extract (likely containing collagen-derived peptides) from animal tissues that is not FDA-approved and has essentially no published safety data in medical literature. As an undefined and poorly characterized biological mixture, batch consistency, sterility, and identity cannot be verified. Potential risks include allergic reactions to animal proteins, contamination from source tissues, and unknown immunological effects. No formal safety assessments, animal studies, toxicology screening, or human clinical trials exist. The product appears to exist primarily in Russian medical markets, and little information about its actual composition or manufacturing is publicly available. Contraindications xKnown hypersensitivity to peptide bioregulators or constituent amino acids (glutamic acid, aspartic acid, proline) xPregnancy and breastfeeding — insufficient reproductive safety data xActive autoimmune disease in flare without physician supervision xOrgan transplant recipients on immunosuppression — potential interference with immunosuppressive regimens Vilon (immunomodulatory thymic peptide complex from bovine thymus) demonstrates favorable safety in Russian/Eastern European medical use over 20+ years with minimal documented serious adverse events in published literature. Bovine-derived peptide preparations carry theoretical prion disease risk (variant Creutzfeldt-Jakob disease) though processing methods and regulatory standards substantially reduce this risk. Common adverse effects are mild—local injection site reactions, transient fever, or lymphadenopathy—consistent with immune system stimulation rather than toxicity. xKnown hypersensitivity to peptide bioregulators or constituent amino acids (lysine, glutamic acid) xActive autoimmune disease in flare without medical supervision Decision Guide

Source: peptideinitiative.com ↗
P

About the author

Peptide Therapy Guide Editorial Team

Editorial team for Peptide Therapy Guide.

View all articles →

Continue learning

Related guides